Logo Image

Authors

Thao K. Adams, PharmD, BCOP
Latest Article

Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin Cancers

New and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.

Bhishamjit S. Chera, MD

Bhishamjit S. Chera, MD is an associate professor was the University of North Carolina- Chapel HIll and director of Patient Safety and Quality in the Department of Radiation Oncolog at UNC Lineberger Comprehensive Cancer Center.

Latest Article

ctDNA Is Improving Oncology Care and Should Be Part of the Standard of Care

Many oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.

Bryan McIver, MD, PhD
Latest Article

McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid Cancer

During a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.

Sanandan Ojha
Latest Article

Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Guilherme Rabinowits, MD
Niyati Nathwani, MD
Latest Article

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Sponsored by Clovis Oncology
Amir Mortazavi, MD
Latest Article

Experts Compare Available Regimens for a Patient With Sarcomatoid Features

During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.

Leif Stenke, MD, PhD
Suzanne Morris, DVM, MWC
Latest Article

SHP2 Inhibitors Undergo Exploration in Combinations

Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.

Jackie Collins
Latest Article

ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial Cancer

An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.

Neil Baum, MD
Latest Article

Six Tips for Identifying Go-Getters for Your Practice

The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.

Gizelka A. David-West, MD
Latest Article

Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance Therapy

Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.

Carlyn Tan, MD
Sarah C. Rutherford, MD
Chris Ryan
Latest Article

Progression Remains Low in CARTITUDE-4 at 3 Years in R/R Myeloma

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

Afton Woodward
Yael Celermajer, MD
Belisario Arango, MD
Belisario Arango, MD

Belisario Arango, MD, is a medical oncologist at Utah Hematology Oncology in Ogden, Utah.

Viral Rabara, MD
Latest Article

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Scott J. Lipkin, DPM
Latest Article

Addressing Clinical Trial Challenges in the Outpatient Setting

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

Courtney Marabella
Latest Article

T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup Analysis

Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.

Gwen Nichols, MD
Latest Article

Medicaid Cuts Create Barriers for Oncologists and Patients With Cancer

Gwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times.

Kristen Pettit, MD
Latest Article

An Update on Current and Emergent Therapies for Essential Thrombocytosis

The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.

Melissa Starowitz
Latest Article

Launching a Medical Practice

Discover essential steps for launching a successful private medical practice, from defining your vision to securing financing and managing finances effectively.

Example
Jax DiEugenio
Latest Article

Progression Remains Low in CARTITUDE-4 at 3 Years in R/R Myeloma

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

Mahesh Swaminathan, MBBS
Latest Article

Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.

Ryan Scott
Latest Article

Adjuvant I-O Combination Is Tied to Early QOL Declines in RCC

The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring, but efficacy came with increased toxicity.

Emily Z. Touloukian
Latest Article

Can Just-in-Time Clinical Trials Reduce Disparities in Participation?

Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.